Yuan Liu

Dr. Yuan Liu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Molecular Biomedicine
Verified
Journal Article
Open access
PDF file
YLYuan Liu
Yuan Liu
LDLianpan Dai
Lianpan Dai
XFXiaoli Feng
Xiaoli Feng
RGRan Gao
Ran Gao
NZNan Zhang
Nan Zhang
MLMinghua Li
Minghua Li
In the face of the emerging variants of SARS-CoV-2, there is an urgent need to develop a vaccine that can induce fast, effective, long-lasting and broad protective immunity against SARS-CoV-2. Here, we developed a trimeric SARS-CoV-2 S protein vaccine candidate adjuvanted by PIKA, which can induce robust cellular and humoral immune responses. The results showed a high level of neutralizing antibodies induced by the vaccine was maintained for at least 400 days. In the study of non-human primates, PIKA adjuvanted S-trimer induced high SARS-CoV-2 neutralization titers and protected from virus replication in the lung following SARS-CoV-2 challenge. In addition, the long-term neutralizing antibody response induced by S-trimer vaccine adjuvanted by PIKA could neutralize multiple SARS-CoV-2 variants and there is no obvious different among the SARS- CoV-2 variants of interest or concern, including B.1.351, B.1.1.7, P.1, B.1.617.1 and B.1.617.2 variants. These data support the utility of S-trimer protein adjuvanted by PIKA as a potential vaccine candidate against SARS-CoV-2 infection.

1 January 2024 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
RLRenan James Lim
Renan James Lim
XQXiangyan Qiu
Xiangyan Qiu
EAEdison Alberto
Edison Alberto
MCMaria Rosario Capeding
Maria Rosario Capeding
JCJosefina Carlos
Josefina Carlos
ZMZenaida Mojares
Zenaida Mojares
Lim RJ, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):329-337. https://doi.org/10.7774/cevr.2024.13.4.329

1 January 2024 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
RLRenan James Lim
Renan James Lim
XQXiangyan Qiu
Xiangyan Qiu
RLRobert Neil Leong
Robert Neil Leong
JGJose Limuel Gutierrez
Jose Limuel Gutierrez
AHAhmad Halima
Ahmad Halima
ZMZenaida Mojares
Zenaida Mojares
Lim RJ, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):315-328. https://doi.org/10.7774/cevr.2024.13.4.315

23 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
YLYuan Liu
Yuan Liu
NZNan Zhang
Nan Zhang
BWBin Wang
Bin Wang
YZYi Zhang
Yi Zhang
Recently SARS-CoV-2 Omicron (B.1.1.529) variant was identified in South Africa with numerous mutations in spike protein, and numerous community infections have been reported and raised grave concern around the world. Some studies found that the neutralization effects of several licensed vaccines against Omicron were dramatically reduced, which significantly affected antibody mediated protection, especially for individuals whose immunization were completed after extended period. In this regard, we studied the persistence and neutralization activity toward mutant strains in animal serum immunized with PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (YS-SC2-010). Here we are reporting that animal serum collected at 596 days after immunization with YS-SC2-010 still retains high and persistent neutralizing activity against all the Variant of Concern (VOC) variants, including Omicron variant. Although it is a blessed event to achieve 20 months long neutralization against Omicron variant after immunization with YS-SC2-010, it was also founded that the neutralization effect of immune serum on Omicron decreased by 6.29 folds as compared to D614G, more significantly when compared with other mutant strains.

2 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ZZZhixian Zhao
Zhixian Zhao
BWBin Wang
Bin Wang
HWHao Wang
Hao Wang
QZQiang Zhang
Qiang Zhang
YLYunfei Liang
Yunfei Liang
YLYuan Liu
Yuan Liu
Background: Currently marketed hepatitis B vaccines are primarily recombinant protein vaccines. However, their antigen immunogenicity is relatively weak, requiring combination with effective adjuvants to enhance the immune response. The development of novel, highly effective adjuvants is a key strategy for optimizing vaccine performance. Polyinosinic-polycytidylic acid (PolyI:C), a synthetic double-stranded RNA analog, activates TLR3/RLR pathways to enhance T-cell priming and cellular immunity. However, its utility as a sole adjuvant is limited by rapid nuclease degradation and poor cytosolic delivery. Lipid nanoparticles (LNPs), a mature delivery platform, enable high encapsulation efficiency, efficient cellular uptake, and endosomal escape. Objectives: This study aimed to evaluate the adjuvant effect of LNP-encapsulated PolyI:C (LNP-PolyI:C) on the immunogenicity of hepatitis B surface antigen (HBsAg) in vivo. Methods: The colloidal stability of LNP-PolyI:C stored at 2–8°C for 9 months was monitored using dynamic light scattering (DLS) on a Zetasizer Lab instrument. Serum levels of HBsAg-specific IgG, IgG1, and IgG2a antibodies in immunized Kunming mice were measured by enzyme-linked immunosorbent assay (ELISA). The secretion of HBsAg-specific cytokines by splenocytes was analyzed using flow cytometry and enzyme-linked immunospot (ELISpot) assay. Results: The results demonstrated that the LNP-encapsulated PolyI:C adjuvant significantly increased the secretion of HBsAg-specific IFN-γ, IL-2, and TNF-α by murine splenocytes, indicating a Th1-biased and cytotoxic T lymphocyte (CTL)-mediated cellular immune response. In addition, this formulation markedly elevated serum titers of HBsAg-specific IgG, IgG1, and IgG2a. Notably, the increased IgG2a/IgG1 ratio highlights a robust enhancement of the humoral immune response. Conclusions: These findings underscore the advantages of the LNP-PolyI:C adjuvant in enhancing both humoral and cellular immunity, demonstrating its considerable potential as a novel adjuvant.